Shares of Ampio Pharmaceuticals were crushed this morning after the biotech acknowledged that its lead drug flunked a Phase III test for osteoarthritis. And the news comes just days after one of its drug subsidiaries was absorbed into a new biotech that will be called Aytu.
Palo Alto CA's Carbylan Therapeutics is developing a Phase III injectable combination therapy for knee osteoarthritis to compete with Sanofi's offering, but in a setback, its planned $75 million IPO was postponed.
AnaMar has rejigged its pipeline priorities after digging through the data from its failed Phase IIa trial. The trial missed its primary endpoint of reducing pain in people with mild to moderate osteoarthritis pain, but a post hoc subgroup analysis has persuaded AnaMar it was trialling the right drug in the wrong indication.
Building on years of research into the anti-inflammatory and tissue-repairing properties of the protein molecule C-type natriuretic peptide, investigators in the U.K. say they have managed to overcome one of the hurdles that has prevented its use for treating osteoarthritis.
Dublin-based Nexvet Biopharma has become the first company to launch a pivotal clinical trial of a monoclonal antibody (mAb) designed to combat pain in dogs with osteoarthritis.
U.K. researchers say they've zeroed in on two new biomarkers that could help predict who will develop osteoarthritis. The hope is that the biomarkers could form the basis of a blood test that enables earlier medical intervention before the condition causes too much damage.
After two stinging rejections sent it back to the lab, Anika Therapeutics has secured the FDA's blessing for an osteoarthritis pain injection, propelling the biotech's shares up more than 40%.
The head of the pharma division, Stefan Oschmann, tells the Financial Times that the Darmstadt-based drug developer is looking to stretch its $1.5 billion annual research budget with some additional cost-sharing deals that might include private equity groups as well as other industry partners.
Shares of Nektar Therapeutics took a nasty plunge Thursday evening after the biotech failed to convince investors that the Phase II flop of a top pain drug didn't tarnish the program's promise.
Imprimis Pharmaceuticals took two major steps this week, gaining approval to begin Phase III clinical trials for its lead osteoarthritis topical cream candidate and getting hold of a novel transdermal treatment for wound management.